Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis

Arthritis Rheum. 2007 Mar;56(3):702-4. doi: 10.1002/art.22448.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Anti-Inflammatory Agents / adverse effects*
  • Anti-Inflammatory Agents / pharmacology
  • Azathioprine / adverse effects*
  • Azathioprine / pharmacology
  • Biopsy
  • Creatinine / blood
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / pharmacology
  • Kidney / drug effects
  • Kidney / pathology*
  • Lupus Nephritis / drug therapy*
  • Lupus Nephritis / pathology
  • Methylprednisolone / adverse effects*
  • Methylprednisolone / pharmacology
  • Prednisone / adverse effects
  • Prednisone / pharmacology
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Immunosuppressive Agents
  • Cyclophosphamide
  • Creatinine
  • Azathioprine
  • Prednisone
  • Methylprednisolone